IQVIA(US:IQV)2021-07-27 18:35Financial Data and Key Metrics Changes - Revenue for Q2 2021 grew 36.4% on a reported basis and 33.2% at constant currency, reaching $3.438 billion, which was $176 million above the midpoint of guidance [14][25] - Adjusted EBITDA for Q2 increased by 49.5% to $722 million, with first half adjusted EBITDA at $1.466 billion, up 40.3% year-over-year [29] - Adjusted diluted EPS for Q2 was $2.13, reflecting an 80.5% increase, and first half adjusted net income was $841 million or $4.32 per share [30] Business Line Data and Key Metrics Changes - Technology & Analytics Solutions revenue for Q2 was $1.353 billion, up 22% reported and 17.9% at constant currency [26] - R&D Solutions revenue for Q2 was $1.891 billion, up 53.1% at actual FX rate and 50.7% at constant currency, with a contracted net book-to-bill ratio of 1.34 [27][21] - CSMS revenue for Q2 was $194 million, growing 9.6% reported and 7.3% at constant currency [28] Market Data and Key Metrics Changes - The life sciences industry is experiencing strong health, with new clinical trial starts up 22% versus 2020 levels and 7% compared to 2019 [8] - Biotech funding reached $25 billion in the first half of 2021, a 64% increase compared to the first half of 2020 [10] Company Strategy and Development Direction - The company is focused on leveraging its differentiated capabilities in data analytics and advanced technology to drive demand for clinical and commercial offerings [11][12] - Plans for 2022 include hosting an investor conference to update on progress and future plans [13] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in continued strong demand for services, driven by the health of the life sciences industry and the company's capabilities [12] - The company raised its full-year 2021 revenue guidance by $275 million, reflecting strong operational momentum [33] Other Important Information - The company completed the acquisition of the remaining interest in Q2 Solutions and plans to expand laboratory operations [23] - The company is also acquiring Myriad RBM to enhance capabilities in biomarker detection and quantification testing [24] Q&A Session Summary Question: Insights on cash flow performance and future outlook - Management highlighted strong cash flow performance driven by earnings growth and improved billing terms, targeting cash flow in the range of 80% to 90% of adjusted net income [41][42] Question: COVID-related revenue insights - COVID vaccine trials represent less than 5% of total backlog, with expectations for COVID work to continue into 2022 and beyond [47][50] Question: Organic revenue growth metrics for each segment - Organic growth for segments is essentially equal to reported growth due to minimal acquisition contributions [54] Question: Real-world evidence business size and growth - The real-world evidence business is approximately $1 billion and continues to grow in double digits, contributing significantly to overall business growth [55] Question: Staffing environment and labor shortages - Management acknowledged strong competition for talent but expressed confidence in attracting and retaining employees due to the company's reputation and investment in staff [60][61] Question: Backlog growth and site accessibility concerns - Backlog grew 16.7% year-over-year, with site access approaching 80%, allowing for continued project execution [65][67] Question: Decentralized trial offering updates - The decentralized trial offering has matured, with over 81 trials fully deployed on Study Hub, and the company is seeing increased demand from top pharma clients [100] Question: M&A landscape and share gains - The company is observing consolidation in the industry, which may present opportunities for share gains, but does not feel the need to participate in M&A actively [108][110]